×
About 2,101 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  1,027 results

Necrotising myopathy and concurrent thyroiditis in a patient with COVID-19 infection.
https://doi.org/10.1136/bcr-2021-242234
BMJ Case Reports; Reggio C, Paudel A et. al.

Jun 4th, 2021 - A 76-year-old man with hypogammaglobulinemia on monthly intravenous immunoglobulin infusions presented to the hospital with fever, cough, and shortness of breath and was diagnosed with COVID-19 pneumonia requiring intensive care unit admission but...

Novel STAT3 gain-of-function variant with hypogammaglobulinemia and recurrent infection...
https://doi.org/10.1111/cei.13625
Clinical and Experimental Immunology; Erdős M, Tsumura M et. al.

May 29th, 2021 - Signal transducer and activator of transcription 3 (STAT3) gain-of-function (GOF) syndrome is an early-onset monogenic inborn error of immunity characterized by multi-organ autoimmune disorders, growth failure and lymphoproliferation. We describe ...

The Heart of the Matter: Secondary Hypogammaglobulinemia and Constrictive Pericarditis.
https://doi.org/10.1542/peds.2020-021808
Pediatrics Schmitt EG, Dalal AS et. al.

May 29th, 2021 - Constrictive pericarditis is the final common result of a number of processes that affect the pericardium. Establishing the diagnosis and determining the underlying etiology of constrictive pericarditis are often a diagnostic rendezvous. Here, we ...

Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
https://doi.org/10.1016/j.jaci.2021.03.041
The Journal of Allergy and Clinical Immunology; Labrosse R, Barmettler S et. al.

Apr 16th, 2021 - Rituximab is a B-cell depleting agent used in B-cell malignancies and autoimmune diseases. A subset of adult patients may develop prolonged and symptomatic hypogammaglobulinemia following rituximab treatment. However, this phenomenon has not been ...

A Novel Homozygous TRNT1 Mutation in a Child With an Early Diagnosis of Common Variable...
https://doi.org/10.1097/MPH.0000000000002101
Journal of Pediatric Hematology/oncology; Topyildiz E, Edeer Karaca N et. al.

Apr 12th, 2021 - Although sideroblastic anemias (SAs) may be associated with different etiologies, deterioration of mitochondrial heme biosynthesis in bone marrow erythroid cells is a general abnormality. Congenital SA associated with immunodeficiency, periodic fe...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  1,047 results

Necrotising myopathy and concurrent thyroiditis in a patient with COVID-19 infection.
https://doi.org/10.1136/bcr-2021-242234
BMJ Case Reports; Reggio C, Paudel A et. al.

Jun 4th, 2021 - A 76-year-old man with hypogammaglobulinemia on monthly intravenous immunoglobulin infusions presented to the hospital with fever, cough, and shortness of breath and was diagnosed with COVID-19 pneumonia requiring intensive care unit admission but...

Novel STAT3 gain-of-function variant with hypogammaglobulinemia and recurrent infection...
https://doi.org/10.1111/cei.13625
Clinical and Experimental Immunology; Erdős M, Tsumura M et. al.

May 29th, 2021 - Signal transducer and activator of transcription 3 (STAT3) gain-of-function (GOF) syndrome is an early-onset monogenic inborn error of immunity characterized by multi-organ autoimmune disorders, growth failure and lymphoproliferation. We describe ...

The Heart of the Matter: Secondary Hypogammaglobulinemia and Constrictive Pericarditis.
https://doi.org/10.1542/peds.2020-021808
Pediatrics Schmitt EG, Dalal AS et. al.

May 29th, 2021 - Constrictive pericarditis is the final common result of a number of processes that affect the pericardium. Establishing the diagnosis and determining the underlying etiology of constrictive pericarditis are often a diagnostic rendezvous. Here, we ...

Risk for Hypogammaglobulinemia, Infections With Rituximab Increased in Pediatric Patients
https://www.medscape.com/viewarticle/949577

Apr 19th, 2021 - A quarter of children receiving treatment with rituximab developed hypogammaglobulinemia within 18 months of starting the drug, according to preliminary research shared at the annual scientific meeting of the Childhood Arthritis and Rheumatology R...

Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
https://doi.org/10.1016/j.jaci.2021.03.041
The Journal of Allergy and Clinical Immunology; Labrosse R, Barmettler S et. al.

Apr 16th, 2021 - Rituximab is a B-cell depleting agent used in B-cell malignancies and autoimmune diseases. A subset of adult patients may develop prolonged and symptomatic hypogammaglobulinemia following rituximab treatment. However, this phenomenon has not been ...

see more →

News  23 results

Risk for Hypogammaglobulinemia, Infections With Rituximab Increased in Pediatric Patients
https://www.medscape.com/viewarticle/949577

Apr 19th, 2021 - A quarter of children receiving treatment with rituximab developed hypogammaglobulinemia within 18 months of starting the drug, according to preliminary research shared at the annual scientific meeting of the Childhood Arthritis and Rheumatology R...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.staging.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Hypogammaglobulinemia and infection risk clarified in MS patients on anti-CD20 agents
https://www.mdedge.com/multiplesclerosishub/article/209320/multiple-sclerosis/hypogammaglobulinemia-and-infection-risk/page/0/1

Oct 2nd, 2019 - Ocrelizumab Tobias Derfuss, MD, provided data on infection rates in the pivotal phase 3 OPERA and ORATIO double-blind clinical trials combined with their long-term, open-label extensions totaling 288 weeks, or nearly 6 years, of follow-up. Serum I.

Plerixafor produced dramatic responses in severe WHIM syndrome
https://www.mdedge.com/familymedicine/article/192393/anemia/plerixafor-produced-dramatic-responses-severe-whim-syndrome
MDedge Hematology and Oncology; Amy Karon

Jan 9th, 2019 - Low-dose treatment with plerixafor, a CXC chemokine receptor 4 antagonist, was well tolerated and markedly improved severe presentations of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome in three patients who could not.

see more →